|
UBE4A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.04680000013025E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.91439999999555E-05 |
| Normal-vs-Stage2 |
2.183200E-03 |
| Normal-vs-Stage3 |
9.71079999745328E-08 |
| Normal-vs-Stage4 |
1.05070000000484E-06 |
| Stage1-vs-Stage2 |
9.543200E-01 |
| Stage1-vs-Stage3 |
1.896470E-02 |
| Stage1-vs-Stage4 |
3.847800E-02 |
| Stage2-vs-Stage3 |
8.722200E-02 |
| Stage2-vs-Stage4 |
7.203900E-02 |
| Stage3-vs-Stage4 |
7.825400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.70060000029382E-07 |
| Normal-vs-AfricanAmerican |
1.502400E-02 |
| Normal-vs-Asian |
7.615800E-04 |
| Caucasian-vs-AfricanAmerican |
5.935800E-01 |
| Caucasian-vs-Asian |
5.761000E-01 |
| AfricanAmerican-vs-Asian |
9.119000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.51089999955722E-07 |
| Normal-vs-Female |
1.53336999999532E-05 |
| Male-vs-Female |
9.052500E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.611000E-04 |
| Normal-vs-Age(41-60Yrs) |
2.23109999997195E-06 |
| Normal-vs-Age(61-80Yrs) |
1.33920000000565E-06 |
| Normal-vs-Age(81-100Yrs) |
2.618700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.394380E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.070300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.037150E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.810800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.647000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.836200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.268130E-02 |
| Classical-VS-Follicular |
1.554770E-01 |
| Classical-VS-Other |
2.692800E-01 |
| Classical-VS-Normal |
7.67280000000259E-05 |
| Tall-VS-Follicular |
1.153440E-01 |
| Tall-VS-Other |
8.333200E-01 |
| Tall-VS-Normal |
6.62519999972133E-07 |
| Follicular-VS-Other |
5.794600E-01 |
| Follicular-VS-Normal |
7.83920000000382E-05 |
| Other-VS-Normal |
1.682230E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.05889999996367E-06 |
| Normal-vs-N1 |
1.52090999999688E-05 |
| N0-vs-N1 |
4.565400E-01 |
|
|
